← Leaderboards
Michelle L Hermiston
University Of California San Francisco
$3,634,874
Attributed
$7,716,390
Total exposure
3
Grants
1
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $851.6K · FY2005–25$1M$750K$500K$250K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$7,716,390 · 3
By mechanism
R01$7,334,880 · 2
K08$381,510 · 1
Top collaborators
- Terzah M Horton8 shared
- David T. Teachey8 shared
- Brent L Wood8 shared
Most similar at University Of California San Francisco
Same institution · by research overlap
- Allan Balmain$39,243,725
- Frank Patrick McCormick$56,513,144
- Jonathan S. Weissman$11,867,986
- Carol A Gross$25,552,015
- Nina Agabian$4,154,459
Others in their field
Top investigators on “Response”
- Lawrence Corey · Fred Hutchinson Cancer Center$677,505,141
- David Divins · Consortium For Ocean Leadership, Inc$609,772,544
- Margaret Juliana McElrath · Fred Hutchinson Cancer Center$532,027,174
- Barton F Haynes · Duke University$497,761,007
- Jeffrey P Krischer · University Of South Florida$397,532,270
- Glenda E Gray · Wits Health Consortium (Pty), Ltd$342,310,423
Research focus
ResponseCellsT-LymphocyteMutationSignal TransductionSignal PathwayBiochemicalPhenotypeGeneticProteasome InhibitorInternationalHigh RiskPediatric Oncology GroupPathway InteractionsProteinsGenesBone MarrowClinical TrialsChemotherapyBiologyDisease-Free SurvivalCytotoxic ChemotherapyChildBortezomib
Grant awards (16)
Improving risk allocation and developing novel therapies for children with T-ALL and T-LL$737,926
R01 · FY2025 · CA
Improving risk allocation and developing novel therapies for children with T-ALL and T-LL$721,069
R01 · FY2024 · CA
Improving risk allocation and developing novel therapies for children with T-ALL and T-LL$851,561
R01 · FY2023 · CA
Improving risk allocation and developing novel therapies for children with T-ALL$575,456
R01 · FY2019 · CA
Improving risk allocation and developing novel therapies for children with T-ALL$594,741
R01 · FY2018 · CA
Improving risk allocation and developing novel therapies for children with T-ALL$625,779
R01 · FY2017 · CA
Improving risk allocation and developing novel therapies for children with T-ALL$626,176
R01 · FY2016 · CA
Improving risk allocation and developing novel therapies for children with T-ALL$709,314
R01 · FY2015 · CA
Interplay of Innate and Adaptive Immunity in Lupus Pathogenesis$382,388
R01 · FY2014 · AI · contact PI
Interplay of Innate and Adaptive Immunity in Lupus Pathogenesis$359,444
R01 · FY2013 · AI · contact PI
Interplay of Innate and Adaptive Immunity in Lupus Pathogenesis$382,388
R01 · FY2012 · AI · contact PI
Interplay of Innate and Adaptive Immunity in Lupus Pathogenesis$382,388
R01 · FY2011 · AI · contact PI
Interplay of Innate and Adaptive Immunity in Lupus Pathogenesis$386,250
R01 · FY2010 · AI · contact PI
Role of CD45 in Hematopoiesis and Lymphomagenesis$127,170
K08 · FY2005 · CA
Role of CD45 in Hematopoiesis and Lymphomagenesis$127,170
K08 · FY2004 · CA
Role of CD45 in Hematopoiesis and Lymphomagenesis$127,170
K08 · FY2003 · CA